In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Allogene Therapeutics (ALLO), with a price target of ...
The post Canaccord Genuity Thinks Allogene Therapeutics Stock is Going to Recover appeared first on Smarter Analyst.
In a report released yesterday, ...

https://www.smarteranalyst.com/new-blurbs/canaccord-genuity-thinks-allogene-therapeutics-stock-is-going-to-recover/

#SmarterAnalyst